chr15-66435117-G-C
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP2PP3_Moderate
The NM_002755.4(MAP2K1):c.171G>C(p.Lys57Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Consequence
NM_002755.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MAP2K1 | NM_002755.4 | c.171G>C | p.Lys57Asn | missense_variant | Exon 2 of 11 | ENST00000307102.10 | NP_002746.1 | |
MAP2K1 | NM_001411065.1 | c.105G>C | p.Lys35Asn | missense_variant | Exon 2 of 10 | NP_001397994.1 | ||
MAP2K1 | XM_011521783.4 | c.105G>C | p.Lys35Asn | missense_variant | Exon 2 of 11 | XP_011520085.1 | ||
MAP2K1 | XM_017022411.3 | c.171G>C | p.Lys57Asn | missense_variant | Exon 2 of 10 | XP_016877900.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Arteriovenous malformation Pathogenic:1
A MAP2K1 c.171G>C (p.Lys57Asn) variant was identified at an allelic fraction consistent with somatic origin. This same amino acid change (p.Lys57Asn) due to a different nucleotide change (c.171G>T) has been reported in multiple individuals with arteriovenous malformations (Couto JA et al., PMID: 28190454; Maurus K et al., PMID: 34726260; Schmidt VF et al., PMID: 38563363; Zenner K et al., PMID: 32884133). The MAP2K1 c.171G>C (p.Lys57Asn) variant has also been identified in numerous cases in the cancer database COSMIC (Genomic Mutation ID: COSV61070413). It is absent from the general population (gnomAD v.4.1.0), indicating it is not a common variant. It resides within the negative regulatory region of the MEK1 protein that is defined as a critical functional domain (Waterfall JJ et al., PMID: 24241536) and where pathogenic variants are known to cluster (Dentici ML et al., PMID: 19156172). Another variant in the same codon, c.169A>C (p.Lys57Gln), has been reported in affected individuals and is considered likely pathogenic (ClinVar ID: 40779). Functional studies show that the MAP2K1 (p.Lys57Asn) variant confers a gain of function to MEK1 as demonstrated by increased autophosphorylation and phosphorylation of downstream ERK and ribosomal protein S6 kinase (RSK), leading to increased cell viability, proliferation, and transformation, as well as resistance to some MEK and BRAF inhibitors (Marks JL et al., PMID: 18632602; Kinoshita-Kikuta E et al., PMID: 29753091; Grisham RN et al., PMID: 26324360; Ng PKS et al., PMID: 29533785; Arcila ME et al., PMID: 25351745; Mizuno S et al., PMID: 36442478). The MAP2K1 gene is defined by the ClinGen RASopathy expert panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (Gelb BD, et al., PMID: 29493581). Based on available information and an internally developed protocol informed by the ACMG/AMP guidelines for variant interpretation and gene-specific practices from the ClinGen Criteria Specification Registry (Leon-Quintero FZ et al., PMID: 39434542), the MAP2K1 c.171G>C (p.Lys57Asn) variant is classified as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at